Biotech Values

[Kadaicher1]

PRW. The more I read, the better it looks. All patients in the trial had previously been treated with 5FU. Patients have to be taken of 5FU due to toxicity, not because they become refractory. Davanat eliminates toxicity. They saw tumour shrinkage in 43% of patients taking the 5FU/Davanat. Thats pretty good, considering it should be first line.